Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial

Autor: Erlinge, David, Andersson, Jonas, Fröbert, Ole, Törnerud, Mattias, Hamid, Mehmet, Kellerth, Thomas, Grimfjärd, Per, Winnberg, Oscar, Jurga, Juliane, Wagner, Henrik, Zwackman, Sammy, Adielsson, Martin, Alström, Patrik, Masoe, Elli, Ulvenstam, Anders, Millgård, Jonas, Böhm, Felix, Held, Claes, Renlund, Henrik, Oldgren, Jonas, Smits, Pieter C, Elek, Candace, Abizaid, Andrea, James, Stefan
Zdroj: The Lancet; November 2024, Vol. 404 Issue: 10464 p1750-1759, 10p
Abstrakt: Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention (PCI) remain a challenge. A bioadaptor is a novel implant that addresses this issue by restoring the haemodynamic modulation of the artery, allowing cyclic pulsatility, vasomotion, and adaptative remodelling, by unlocking and providing dynamic support to the artery. We aimed to assess outcomes with the device versus a contemporary drug-eluting stent (DES) in a representative PCI population.
Databáze: Supplemental Index